Chimerix
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.
Oncoceutics
Acquisition in 2021
Oncoceutics, Inc. is a clinical-stage drug discovery and development company based in Philadelphia, Pennsylvania, founded in 2009. The company focuses on developing therapeutics that target critical signaling pathways in cancer. Its lead compound, ONC201, is an orally active DRD2 small molecule antagonist known for its significant anti-tumor activity across various cancer types through a unique mechanism of action. ONC201 has demonstrated compelling preclinical efficacy and a favorable safety profile, making it a promising candidate for clinical use. The company is actively conducting clinical trials for ONC201 at leading cancer centers globally, aiming to provide safe and effective treatment options for patients with advanced cancers. Additionally, Oncoceutics maintains strategic alliances with organizations such as the National Institutes of Health and Calvert Research, LLC, to enhance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.